Tarsus Pharmaceuticals, Inc. TARS Business Segments — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s business segments — cost of sales?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — cost of sales of $9.4M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — cost of sales changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — cost of sales increased by 80.3% year-over-year, from $5.21M to $9.4M.
- What does business segments — cost of sales mean?
- Includes the direct costs attributable to the production and distribution of the goods sold by the business segment. Monitoring this helps evaluate the direct profitability and manufacturing efficiency of the company's commercialized products.